Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and DLI for Prevention of AML Recurrence After Haplo-HSCT
NCT06754540Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), sponsored by Shanghai General Hospital. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06754540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754540.